Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the...
Learn more
Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s.
Moving towards a new staging system for Parkinson’s
Cure Parkinson’s has been a part of a group of Parkinson’s scientists, charity organizations, and patient advocates from around the world to help develop a new biological staging framework for Parkinson’s.
2024: research highlights of last year and the year ahead
With the announcement of some very encouraging results from completed clinical trials last year, and a number of promising new projects focused on disease modification – the outlook for 2024 is looking good!
Alpha-synuclein or Tau in Parkinson’s?
The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.
Exploring Perspectives on Trial Design for Parkinson’s: An Update on the Delphi Study
Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.